Extracorporeal Shock Wave Enhances the Cisplatin Efficacy by Improving Tissue Infiltration and Cellular Uptake in an Upper Urinary Tract Cancer Animal and Human-Derived Organoid Model

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Sep 28

PMID 34572785

Citations 6

Authors

Hao-Lun Luo

Hui-Ying Liu

Yin-Lun Chang

Yu-Li Su

Chun-Chieh Huang

Xin-Jie Lin

Yao-Chi Chuang

Affiliations

Soon will be listed here.

Abstract

Upper urinary tract urothelial carcinoma (UTUC) is a relatively rare cancer with a poor prognosis if diagnosed at an advanced stage. Although cisplatin-based chemotherapy is a common treatment strategy, it has a limited response rate. Shock wave lithotripsy is a common treatment for upper urinary tract stones. Low-energy shock waves (LESWs) temporarily increase tissue permeability and enhance drug penetration to the targeted tissue. However, no study has investigated the efficacy of the combination of shock wave lithotripsy and chemotherapy in UTUC. Hence, in this study, we aimed to identify the potential application of the combination of LESW and chemotherapy in UTUC. We evaluated the synergistic effects of LESW and cisplatin in vitro, in vivo, and in patient-derived organoid (PDO) models. Compared with cisplatin alone, the combination treatment caused more significant tumour suppression in vitro and in animal models, without increased toxicity. Histological examination showed that compared with animals treated with cisplatin alone, those who received the combination treatment showed more deteriorated cell arrangement and cell oedema. Moreover, LESW improved the cytotoxicity of cisplatin in the preclinical PDO model of UTUC. Thus, LESW combined with cisplatin is a potential new antitumour strategy for improving the treatment response in locally advanced UTUC.

Citing Articles

Advancing cancer research through organoid technology.

Zeng G, Yu Y, Wang M, Liu J, He G, Yu S J Transl Med. 2024; 22(1):1007.

PMID: 39516934 PMC: 11545094. DOI: 10.1186/s12967-024-05824-1.

Antibacterial and therapeutic effects of low energy shock waves on uropathogenic E. coli investigated by in vitro and in vivo cystitis rat model.

Wu Z, Kao C, Wang H, Lee W, Luo H, Huang C Int Urol Nephrol. 2024; 57(1):49-61.

PMID: 39078466 DOI: 10.1007/s11255-024-04173-8.

Mutational pattern off homologous recombination repair (HRR)-related genes in upper tract urothelial carcinoma.

Yang K, Yu W, Liu H, Lou F, Cao S, Wang H Cancer Med. 2023; 12(14):15304-15316.

PMID: 37387466 PMC: 10417099. DOI: 10.1002/cam4.6175.

New Frontiers of Extracorporeal Shock Wave Medicine in Urology from Bench to Clinical Studies.

Chen P, Cheng J, Wu Z, Chuang Y Biomedicines. 2022; 10(3).

PMID: 35327477 PMC: 8945448. DOI: 10.3390/biomedicines10030675.

Use of the Shock Wave Therapy in Basic Research and Clinical Applications-From Bench to Bedsite.

Rola P, Wlodarczak A, Barycki M, Doroszko A Biomedicines. 2022; 10(3).

PMID: 35327369 PMC: 8944950. DOI: 10.3390/biomedicines10030568.

References

Margulis V, Shariat S, Matin S, Kamat A, Zigeuner R, Kikuchi E . Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009; 115(6):1224-33. DOI: 10.1002/cncr.24135. View

Lee S, Hu W, Matulay J, Silva M, Owczarek T, Kim K . Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell. 2018; 173(2):515-528.e17. PMC: 5890941. DOI: 10.1016/j.cell.2018.03.017. View

Gunti S, Hoke A, Vu K, London Jr N . Organoid and Spheroid Tumor Models: Techniques and Applications. Cancers (Basel). 2021; 13(4). PMC: 7922036. DOI: 10.3390/cancers13040874. View

Chuang Y, Huang T, Tyagi P, Huang C . Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves. J Urol. 2016; 196(2):599-608. DOI: 10.1016/j.juro.2015.12.078. View

Hoffmann A, Wild P, Leicht C, Bertz S, Danenberg K, Danenberg P . MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia. 2010; 12(8):628-36. PMC: 2915407. DOI: 10.1593/neo.10402. View

Adeldaeim H, Abouyoussif T, El Gebaly O, Assem A, Wahab M, Rashad H . Prognostic Indicators for Successful Low-intensity Extracorporeal Shock Wave Therapy Treatment of Erectile Dysfunction. Urology. 2020; 149:133-139. DOI: 10.1016/j.urology.2020.12.019. View

Kaag M, OMalley R, OMalley P, Godoy G, Chen M, Smaldone M . Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010; 58(4):581-7. PMC: 3677959. DOI: 10.1016/j.eururo.2010.06.029. View

Pena M, Delgado-Gonzalez E, Lopez-Marin L, Millan-Chiu B, Fernandez F, Rodriguez-Castelan J . Shock Wave Application Increases the Antineoplastic Effect of Molecular Iodine Supplement in Breast Cancer Xenografts. Ultrasound Med Biol. 2019; 46(3):649-659. DOI: 10.1016/j.ultrasmedbio.2019.11.015. View

Yang M, Yen C, Chang Y, Hsieh R, Liu J, Chiou T . Single agent paclitaxel as a first-line therapy in advanced urothelial carcinoma: its efficacy and safety in patients even with pretreatment renal insufficiency. Jpn J Clin Oncol. 2001; 30(12):547-52. DOI: 10.1093/jjco/hyd142. View

10.

Tanji N, Fukumoto T, Miura N, Yanagihara Y, Shirato A, Azuma K . Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency. Int J Clin Oncol. 2012; 18(5):910-5. DOI: 10.1007/s10147-012-0466-9. View

11.

Massari F, Santoni M, Di Nunno V, Cheng L, Lopez-Beltran A, Cimadamore A . Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. Cancer Treat Rev. 2018; 68:80-85. DOI: 10.1016/j.ctrv.2018.06.002. View

12.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K . Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018; 359(6378):920-926. PMC: 6112415. DOI: 10.1126/science.aao2774. View

13.

Vinette V, Placet M, Arguin G, Gendron F . Multidrug Resistance-Associated Protein 2 Expression Is Upregulated by Adenosine 5'-Triphosphate in Colorectal Cancer Cells and Enhances Their Survival to Chemotherapeutic Drugs. PLoS One. 2015; 10(8):e0136080. PMC: 4546675. DOI: 10.1371/journal.pone.0136080. View

14.

Calandrini C, Schutgens F, Oka R, Margaritis T, Candelli T, Mathijsen L . An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nat Commun. 2020; 11(1):1310. PMC: 7066173. DOI: 10.1038/s41467-020-15155-6. View

15.

Hsiao C, Lin C, Hou Y, Ko J, Wang C . Low-Energy Extracorporeal Shock Wave Ameliorates Streptozotocin Induced Diabetes and Promotes Pancreatic Beta Cells Regeneration in a Rat Model. Int J Mol Sci. 2019; 20(19). PMC: 6801760. DOI: 10.3390/ijms20194934. View

16.

Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L . Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. Cell Stem Cell. 2019; 26(1):17-26.e6. DOI: 10.1016/j.stem.2019.10.010. View

17.

Liao Y, Gose J, Arruda E, Liu A, Merajver S, Young Y . Shock wave impact on the viability of MDA-MB-231 cells. PLoS One. 2020; 15(6):e0234138. PMC: 7272042. DOI: 10.1371/journal.pone.0234138. View

18.

Kopper O, de Witte C, Lohmussaar K, Espejo Valle-Inclan J, Hami N, Kester L . An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019; 25(5):838-849. DOI: 10.1038/s41591-019-0422-6. View

19.

Ha C, Lee S, Kim S, Chung J, Bae H, Kwon K . Novel mechanism of gene transfection by low-energy shock wave. Sci Rep. 2015; 5:12843. PMC: 4525295. DOI: 10.1038/srep12843. View

20.

Elkashef A, Barakat N, Khater S, Awadalla A, Belal F, El-Assmy A . Effect of low-energy shock wave therapy on intravesical epirubicin delivery in a rat model of bladder cancer. BJU Int. 2020; 127(1):80-89. DOI: 10.1111/bju.15173. View